{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:07:27Z","timestamp":1788516447845,"version":"build-2803163510"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Despite widespread immunization with the 23-valent pneumococcal polysaccharide vaccine (PPSV23), safety concerns remain owing to a lack of statistical power and largely outdated evidence.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate the association between cardiovascular, neurological, and immunological adverse events and PPSV23 vaccination in older adults.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This population-based cohort study using a self-controlled risk interval design used a large linked database created by linking the Korea Immunization Registry Information System and the National Health Information Database (2018 to 2021). Participants included patients aged 65 years or older with a history of PPSV23 vaccination and incident cardiovascular, neurological, or immunological events during the risk and control intervals. Data were analyzed from November 2022 to April 2023.<\/jats:p><\/jats:sec>Exposure<\/jats:title>23-valent pneumococcal polysaccharide vaccine.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The occurrence of 1 among 6 cardiovascular events (myocardial infarction, atrial fibrillation, cardiomyopathy, heart failure, hypotension, and myocarditis or pericarditis), 2 neurological events (Bell palsy and Guillain-Barr\u00e9 syndrome), and 3 immunological events (sepsis, thrombocytopenia, and anaphylaxis) during the risk and control periods. The risk and control intervals were defined as 1 to 28 and 57 to 112 days after PPSV23 vaccination, respectively. Conditional Poisson regression was used to estimate the incidence rate ratio (IRR) with a 95% CI.<\/jats:p><\/jats:sec>Results<\/jats:title>Altogether, 4355 of the 1\u202f802\u202f739 individuals who received PPSV23 vaccination and experienced at least 1 outcome event were included (mean [SD] age, 72.4 [8.2] years; 2272 male participants [52.1%]). For cardiovascular events, there were no significant associations for myocardial infarction (IRR, 0.96; 95% CI, 0.81-1.15), heart failure (IRR, 0.85; 95% CI, 0.70-1.04), and stroke (IRR, 0.92; 95% CI, 0.84-1.02). Similarly, no increased risks were observed for neurological and immunological outcomes: Bell palsy (IRR, 0.95; 95% CI, 0.72-1.26), Guillain-Barr\u00e9 syndrome (IRR, 0.27; 95% CI, 0.06-1.17), sepsis (IRR, 0.99; 95% CI, 0.74-1.32), and thrombocytopenia (IRR, 1.18; 95% CI, 0.60-2.35).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this self-controlled risk interval study, there was no appreciable increase in risk for most cardiovascular, neurological, or immunological adverse events following PPSV23. The updated safety profile of PPSV23 provides supportive evidence for the establishment of immunization strategies for older adults.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.52597","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T16:32:10Z","timestamp":1705941130000},"page":"e2352597","source":"Crossref","is-referenced-by-count":10,"title":["Cardiovascular, Neurological, and Immunological Adverse Events and the 23-Valent Pneumococcal Polysaccharide Vaccine"],"prefix":"10.1001","volume":"7","author":[{"given":"Dongwon","family":"Yoon","sequence":"first","affiliation":[{"name":"School of Pharmacy, Sungkyunkwan University, South Korea"},{"name":"Department of Biohealth Regulatory Science, School of Pharmacy, Sungkyunkwan University, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha-Lim","family":"Jeon","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Institute of New Drug Development, Jeonbuk National University, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Hwan","family":"Kim","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Sungkyunkwan University, South Korea"},{"name":"Department of Biohealth Regulatory Science, School of Pharmacy, Sungkyunkwan University, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyesung","family":"Lee","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Sungkyunkwan University, South Korea"},{"name":"Department of Biohealth Regulatory Science, School of Pharmacy, Sungkyunkwan University, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Young","family":"Shin","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Sungkyunkwan University, South Korea"},{"name":"Department of Biohealth Regulatory Science, School of Pharmacy, Sungkyunkwan University, South Korea"},{"name":"Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,1,22]]},"reference":[{"issue":"2","key":"zoi231543r1","doi-asserted-by":"publisher","first-page":"132","DOI":"10.5124\/jkma.2023.66.2.132","article-title":"Cause-of-death statistics in 2020 in the Republic of Korea.","volume":"66","author":"Noh","year":"2023","journal-title":"J Korean Med Assoc"},{"issue":"46","key":"zoi231543r3","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.15585\/mmwr.mm6846a5","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged =65 years: updated recommendations of the Advisory Committee on Immunization Practices.","volume":"68","author":"Matanock","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9","key":"zoi231543r4","doi-asserted-by":"publisher","first-page":"780","DOI":"10.5124\/jkma.2014.57.9.780","article-title":"Pneumococcal vaccine.","volume":"57","author":"Song","year":"2014","journal-title":"J Korean Med Assoc"},{"issue":"2","key":"zoi231543r5","first-page":"67","article-title":"Pneumococcal vaccination rate and related factors in older adults in republic of Korea.","volume":"46","author":"Lee","year":"2021","journal-title":"J Agric Med Community Health"},{"issue":"7","key":"zoi231543r6","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/jama.2015.63","article-title":"Use of pneumococcal vaccine in adults.","volume":"313","author":"Pisano","year":"2015","journal-title":"JAMA"},{"issue":"35","key":"zoi231543r7","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1016\/j.vaccine.2013.04.085","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"issue":"17","key":"zoi231543r8","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1001\/jama.2010.529","article-title":"Pneumococcal vaccination and risk of acute myocardial infarction and stroke in men.","volume":"303","author":"Tseng","year":"2010","journal-title":"JAMA"},{"key":"zoi231543r9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jns.2018.01.007","article-title":"The association of adult vaccination with the risk of cerebrovascular ischemia: a systematic review and meta-analysis.","volume":"386","author":"Tsivgoulis","year":"2018","journal-title":"J Neurol Sci"},{"issue":"13","key":"zoi231543r10","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.3390\/jcm11133799","article-title":"Effect of pneumococcal vaccine on mortality and cardiovascular outcomes: a systematic review and meta-analysis.","volume":"11","author":"Jaiswal","year":"2022","journal-title":"J Clin Med"},{"issue":"3","key":"zoi231543r11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3349\/ymj.2020.61.3.243","article-title":"Signal detection of adverse events following pneumococcal vaccines from the Korea Adverse Event Reporting System Database, 2005-2016.","volume":"61","author":"Kim","year":"2020","journal-title":"Yonsei Med J"},{"issue":"2","key":"zoi231543r12","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3390\/vaccines8020242","article-title":"Safety surveillance of pneumococcal vaccine using three algorithms: disproportionality methods, empirical bayes geometric mean, and tree-based scan statistic.","volume":"8","author":"Lee","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"25","key":"zoi231543r13","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1016\/j.vaccine.2016.04.021","article-title":"Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990-2013.","volume":"34","author":"Miller","year":"2016","journal-title":"Vaccine"},{"issue":"3","key":"zoi231543r14","first-page":"799","article-title":"Data resource profile: The National Health Information Database of the National Health Insurance Service in South Korea.","volume":"46","author":"Cheol Seong","year":"2017","journal-title":"Int J Epidemiol"},{"key":"zoi231543r15","doi-asserted-by":"publisher","first-page":"m4931","DOI":"10.1136\/bmj.m4931","article-title":"Association between human papillomavirus vaccination and serious adverse events in South Korean adolescent girls: nationwide cohort study.","volume":"372","author":"Yoon","year":"2021","journal-title":"BMJ"},{"issue":"9","key":"zoi231543r17","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1177\/2047487314549512","article-title":"Association between pneumococcal vaccination and cardiovascular outcomes: a systematic review and meta-analysis of cohort studies.","volume":"22","author":"Vlachopoulos","year":"2015","journal-title":"Eur J Prev Cardiol"},{"issue":"4","key":"zoi231543r18","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/all.v76.4","article-title":"Anaphylaxis following vaccination among children in Asia: a large-linked database study.","volume":"76","author":"Choe","year":"2021","journal-title":"Allergy"},{"issue":"8","key":"zoi231543r19","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/aje\/kwu322","article-title":"A vaccine study design selection framework for the postlicensure rapid immunization safety monitoring program.","volume":"181","author":"Baker","year":"2015","journal-title":"Am J Epidemiol"},{"issue":"7","key":"zoi231543r20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002844","article-title":"Kawasaki disease and 13-valent pneumococcal conjugate vaccination among young children: a self-controlled risk interval and cohort study with null results.","volume":"16","author":"Baker","year":"2019","journal-title":"PLoS Med"},{"key":"zoi231543r21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1038043","article-title":"Myocarditis and pericarditis associated with SARS-CoV-2 vaccines: a population-based descriptive cohort and a nested self-controlled risk interval study using electronic health care data from four European countries.","volume":"13","author":"Bots","year":"2022","journal-title":"Front Pharmacol"},{"issue":"12","key":"zoi231543r22","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1038\/s41591-021-01556-7","article-title":"Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection.","volume":"27","author":"Patone","year":"2021","journal-title":"Nat Med"},{"issue":"2","key":"zoi231543r23","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41591-021-01630-0","article-title":"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection.","volume":"28","author":"Patone","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"zoi231543r24","doi-asserted-by":"publisher","first-page":"16406","DOI":"10.1038\/s41598-022-20118-6","article-title":"Risk of thrombocytopenic, haemorrhagic and thromboembolic disorders following COVID-19 vaccination and positive test: a self-controlled case series analysis in Wales.","volume":"12","author":"Torabi","year":"2022","journal-title":"Sci Rep"},{"issue":"29","key":"zoi231543r25","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1016\/j.vaccine.2018.05.110","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults =50 years of age: a randomized trial.","volume":"36","author":"Mar\u00e9chal","year":"2018","journal-title":"Vaccine"},{"issue":"2","key":"zoi231543r26","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S1473-3099(22)00526-6","article-title":"Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1\/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial.","volume":"23","author":"Platt","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"zoi231543r27","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1080\/21645515.2015.1030550","article-title":"Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults.","volume":"11","author":"Shiramoto","year":"2015","journal-title":"Hum Vaccin Immunother"},{"issue":"11","key":"zoi231543r28","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/j.vaccine.2017.01.063","article-title":"Investigating adverse events following immunisation with pneumococcal polysaccharide vaccine using electronic general practice data.","volume":"35","author":"Trinh","year":"2017","journal-title":"Vaccine"},{"key":"zoi231543r29","doi-asserted-by":"publisher","first-page":"i4515","DOI":"10.1136\/bmj.i4515","article-title":"Self controlled case series methods: an alternative to standard epidemiological study designs.","volume":"354","author":"Petersen","year":"2016","journal-title":"BMJ"},{"key":"zoi231543r30","doi-asserted-by":"publisher","first-page":"l2268","DOI":"10.1136\/bmj.l2268","article-title":"Modernising vaccine surveillance systems to improve detection of rare or poorly defined adverse events.","volume":"365","author":"Chandler","year":"2019","journal-title":"BMJ"},{"issue":"6","key":"zoi231543r33","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy100","article-title":"Pneumococcal conjugate vaccine safety in elderly adults.","volume":"5","author":"Tseng","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"zoi231543r34","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart disease and stroke statistics-2021 update: a report from the American Heart Association.","volume":"143","author":"Virani","year":"2021","journal-title":"Circulation"},{"key":"zoi231543r35","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2022057","article-title":"Epidemiology of myocardial infarction in Korea: hospitalization incidence, prevalence, and mortality.","volume":"44","author":"Kim","year":"2022","journal-title":"Epidemiol Health"},{"issue":"1","key":"zoi231543r36","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/rheumatology\/kez320","article-title":"Methodological considerations when analysing and interpreting real-world data.","volume":"59","author":"St\u00fcrmer","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"zoi231543r16","volume-title":"Report of the evaluation for validity of discharged diagnoses in Korean Health Insurance database","author":"Park","year":"2017"},{"key":"zoi231543r2","unstructured":"Dadonaite? B, Roser? M. Pneumonia. 2018. Accessed June 8, 2023. https:\/\/ourworldindata.org\/pneumonia"},{"key":"zoi231543r31","unstructured":"Centre? UM. What is a signal? 2022. Accessed November 24, 2023. https:\/\/who-umc.org\/signal-work\/what-is-a-signal\/"},{"key":"zoi231543r32","unstructured":"Agency TKDCaP. Streptococcus pneumoniae. Accessed June 13, 2023. https:\/\/nip.kdca.go.kr\/irhp\/infm\/goVcntInfo.do?menuLv=1&menuCd=1206"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2814115\/yoon_2024_oi_231543_1705006708.64406.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T16:32:16Z","timestamp":1705941136000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2814115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.52597","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,22]]}}}